Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s144, 2023. DOI: 10.25251/skin.7.supp.144. Disponível em: https://skin.dermsquared.com/skin/article/view/2025. Acesso em: 17 may. 2025.